Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling History

Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events. The SOLAR-1 trial studied BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and … Συνεχίστε να διαβάζετε Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling History.

Does CAR-T Therapy Have a Payment Problem?

By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and no one was willing to pay for … Συνεχίστε να διαβάζετε Does CAR-T Therapy Have a Payment Problem?.

Sierra Oncology Acquires Gilead’s Momelotinib in $198 Million Deal

Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million. Under the terms of the deal, Sierra is paying Gilead an upfront fee of $3 million. There are various potential milestone payments that could reach up to $195 million. The companies indicate that most of the milestones are commercial ones, rather than … Συνεχίστε να διαβάζετε Sierra Oncology Acquires Gilead’s Momelotinib in $198 Million Deal.